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TRAIL) were available only for SL, while four analytes (MCP-
1, RANTES, TNFR1, and TNFR2) were compatible only with
the LX array. Human serum samples (n=18), stored at -80°C,
represented a subset from the OA Life study, whose subjects
were all obese with knee OA. To compare inter- and intra-assay
variability, serum samples were assayed at three separate times.
After the ﬁrst assay, samples were aliquoted and refrozen for
testing on a different day; thus samples tested on days 2 and
3 were identical and differed from those tested on day 1 by
a single freeze/thaw cycle. The reproducibility of measurement
was analyzed by linear regression and by Intra-Class Correlation
(ICC) both between and within the two platform technologies.
Results: Of the nine analytes common to both SL and LX,
all but IL-8 were consistently detectable on SL, and all but
IL-10 were consistently detectable on LX. The concentrations
measured were generally much higher on LX vs. SL (data not
shown). When data were compared between platforms (e.g.
BDNF measured on SL vs LX), the agreement between SL and
LX was quite low, as seen in ICC values of generally less then 0.4
and R2 values generally less then 0.5 (Table 1). When data were
Table 1. Reliability and correlation of values between SearchLight and Luminex
technologies (measured on days 1, 2, and 3)
Analyte ICC R2
BDNF1 -0.057 0.0022
BDNF2 0.209 0.2286
BDNF3 0.094 0.0519
GCSF1 -0.005 0.0074
GCSF2 0.011 0.0015
GCSF3 -0.004 0.0020
IL-1b1 -0.009 0.2494
IL-1b2 0.011 0.1094
IL-1b3 0.006 0.4958
IL-2 1 -0.013 0.1025
IL-2 2 0.021 0.0315
IL-2 3 0.001 0.0048
IL-6 1 0.020 0.3041
IL-6 2 0.013 0.0471
IL-6 3 0.010 0.0584
IL-8 1 -0.030 N/A
IL-8 2 0.010 N/A
IL-8 3 0.000 N/A
IL-10 1 0.940 N/A
IL-10 2 -0.030 0.0028
IL-10 3 0.030 N/A
IL-1ra 1 0.213 0.6018
IL-1ra 2 0.131 0.1950
IL-1ra 3 0.087 0.1282
VEGF 1 0.336 0.1424
VEGF 2 0.077 0.0085
VEGF 3 0.061 0.0041
Table 2. Intra-Class Correlation (ICC) values for various analytes measured
within each system
Analyte Day 1 vs Day 2 Day 1 vs Day 2 Day 2 vs Day 3
vs Day 3
SL LX SL LX SL LX
BDNF -0.1238 0.8190 -0.1869 0.9303 -0.3316 0.8833
GCSF 0.4630 0.9156 0.7031 0.8476 0.1508 0.9585
IL-1b 0.4103 0.7095 0.4856 0.4320 0.2678 0.9403
IL-2 0.2220 0.9682 0.4413 0.9807 -0.0259 0.9819
IL-6 0.5425 0.8524 0.7026 0.7226 0.3116 0.9430
IL-8 -0.0353 0.9578 0.0000 0.9263 -0.0706 0.9869
IL-10 0.8590 0.7326 0.8879 0.5645 0.7705 0.8378
IL-1ra 0.4771 0.9323 0.7157 0.8751 0.2609 0.9690
Leptin 0.4542 N/A 0.5828 N/A 0.2528 N/A
MCP-1 N/A 0.9384 N/A 0.9062 N/A 0.9617
RANTES N/A 0.3001 N/A 0.4874 N/A 0.3455
TNFR1 N/A 0.9065 N/A 0.8267 N/A 0.9820
TNFR2 N/A 0.8575 N/A 0.7915 N/A 0.9703
TRAIL 0.5162 N/A 0.7511 N/A 0.2499 N/A
VEGF 0.1457 0.8887 0.3291 0.7945 -0.0447 0.9696
log-transformed to minimize the potential effect of outliers, ICC
scores remained low. When data were analyzed within platforms
for each analyte (e.g., BDNF measured on LX on day 1 vs. day 2
vs. Day3) ICC values (Table 2) and R2 values (not shown) were
generally higher for analytes measured by LX than by SL.
Conclusions: In anticipation of measuring cytokine levels across
a number of studies and over several years, we sought to validate
a platform technology which would yield reliable measurements.
At a minimum, our goal was to identify a method sensitive enough
to detect the analytes of interest, and consistent enough to result
in lower assay variability than biologic and inter-subject variability.
LX yielded very consistent measurements (ICCs generally > 0.7)
for all of the detectable analytes except RANTES (ICC = 0.3). In
contrast, SL yielded inconsistent measurements (ICCs generally
< 0.4) for all of the analytes except IL-10 (ICC = 0.86). Thus, in
our hands, and with this panel of analytes, LX proved to be the
superior system in terms of assay reliability.
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Purpose: The CTX II assay has been used to examine the type
II collagen telopeptide concentration in human synovial ﬂuid,
explant media, and urine of rats and humans. These reports
demonstrate that CTX II may be beneﬁcial for diagnosing, pre-
dicting and monitoring changes that occur in osteoarthritis (OA)
patients. Horses are one of the few species in which adequate
volumes of paired synovial ﬂuid, serum, and urine samples can
be collected and compared to allow correlation of this marker
in these different ﬂuids. This may lead to translational beneﬁt to
human OA patients. Type II collagen is well conserved across
species, and the investigators have previously validated the use
of this assay with equine synovial ﬂuid. The purpose was to
validate use of the CTX II assay for use with equine serum for
future use with equine models of OA.
Methods: Serum Pre-Clinical Cartilaps® ELISAs (Nordic Bio-
science Diagnostics) were used according to manufacturer pro-
tocols. Internal quality control (QC) samples were prepared using
the highest concentration standard provided by the manufacturer
(233.3 pg/ml). To create QC samples, fresh serum was collected
aseptically from the jugular vein of 6 normal horses. The samples
were pooled together for further processing and analysis. Pooled
samples were spiked with a known amount of standard to create
samples with high, medium and low levels of CTX II. The QC
samples were used to determine the precision, speciﬁcity, sensi-
tivity, accuracy, linearity of dilution, and stability of this assay with
equine serum. To ensure that the assay could detect different
biological activity, previously stored serum samples were ana-
lyzed from 3 normal horses before (rested) and after 5 months
race-training (exercise), and 3 horses with naturally-occurring
osteochondral (OC) injuries.
Results: Reproducibility of the standard curve was evaluated
(n=6 plates) by computing mean optical density (OD) and per-
cent coefﬁcient of variation (% CV) at each standard concen-
tration. The overall mean inter-assay CV of the standard OD
values was 18.1% (range 11.4-36.9%). Samples exhibited ac-
ceptable intra-assay and inter-assay precision over 3 plates with
an overall mean CV of 4.4% (range; 2.5-9.2%) and 11.9% (range;
10.3-14.4%), respectively. Parallelism and linearity of dilution of
equine serum sample dilutions (1:2, 1:4, 1:8, and 1:10) were
demonstrated (Figure 1). Lowest detection limit of the assay was
determined to be 11.6 pg/ml. Percent recovery was 70% for high,
86% for medium, and 103% for low QC samples. There was no
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Figure 1. The linearity was analyzed by serially diluting (1:2, 1:4, 1:8, and
1:10)the mixed QC samples (MQC) and the unspiked pooled samples (P). The
observed concentration was plotted against the reciprocal of the dilution.
loss in the stability of the CTX II epitope out to 4 freeze/thaw
cycles. Differences in biological activity were identiﬁed when ex-
amining samples from 3 normal rested horses (111.40 ± 33.3
pg/ml), the same horses after 5 months race-training (158.18 ±
111 pg/ml), and those with naturally-occurring OC injuries (38.96
± 12.91 pg/ml) (Figure 2).
Figure 2. Differences in biological activity identiﬁed between samples from 3
horses before (Rested) and after 5 months race-training (Exercised) as well as
3 horses with OA. Signiﬁcant differences between groups are represented as
*P<0.05 using a Kruskal-Wallis test.
Conclusions: The Serum Pre-Clinical Cartilaps® ELISA is a
reproducible and valid assay for use with equine serum.
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Purpose: to evaluate the relationship between OPG and RANKL
in synovial ﬂuid and serum in patients with primary knee os-
teoarthritis and disease severity as it is graded radiologically
according to the system of Kallgren and Lawrence. To demon-
strate the role of the RANKL/OPG system in the pathophysiology
of primary knee osteoarthritis.
Methods: the study population included 37 patients (9 males,
28 females) with mean age 64.9 years (ranging from 50 to 80
years). Synovial ﬂuid was aspirated from the affected joint during
surgery where a total knee arthroplasty was performed. Blood
samples were obtained from the same patients 1 to 2 hours
before surgery. Anteroposterior weight bearing radiographs of
the patients’ knees were performed and osteoarthritic changes
were graded according to the system of Kallgren and Lawrence.
Results: we found that OPG concentration in synovial ﬂuid was
signiﬁcantly higher than in serum (257.5±76.9 vs 49.2±10.1
pmoles/lt, p<0,0001), indicating that the increase of OPG in
patients with knee OA is not systemic but rather localized in
the affected joint. OPG levels were increased in synovial ﬂuid
in relation with the severity of knee OA and were signiﬁcantly
higher in patients with OA grade 4 than in those with grade 1 or
2. RANKL levels were found low in both synovial ﬂuid and serum
(1.5±1.0 and 1.0±1.0 pmoles/lt respectively). Serum levels of
OPG and RANKL did not correlate with the severity of knee OA
Conclusions: based on the fact that OA is characterized by
progressive deterioration of the articular cartilage, the increase
of OPG in synovial ﬂuid of individuals with knee OA might
reﬂect a compensatory response by chondrocytes or synovial
ﬁbroblasts to destabilization of the coupling between degradation
and synthesis of articular cartilage. The increased concentration
of OPG might thus serve to protect cartilage rather than be a
cause of osteoarthritis.
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Purpose: Avocado and Soya (A/S 1:2 w/w) unsaponiﬁables
(ASU), developed and patented by Laboratoires Expanscience,
are the components of a medicinal product found in numerous
countries against degenerative osteoarthritis. The main ingredi-
ents are: 30% tocopherol, 25% sterols and 25% speciﬁc active
molecules. The originality is based on A/S ratio and Avocado
speciﬁc modiﬁed unsaponiﬁables obtained by chemical transfor-
mation of precursors. This modiﬁcation by hemisynthesis con-
stitutes one of the Laboratoires Expanscience know-how and is
patented.
In vitro published studies showed effects of ASU on the an-
abolism (increase in the synthesis of collagens, proteoglycans
and TGFβ) and catabolism (inhibition of synthesis of MMPs,
PGE2, and pro-inﬂammatory cytokines) of osteoarthritic chondro-
cytes. Moreover, clinical studies demonstrated the symptomatic
effect of ASU combined to a reduction in NSAID administration.
The pharmaceutical status requires perfect controls of the extrac-
tion process, of the hemisynthesis from precursors to converted
molecules and an excellent between-batch reproducibility.
This is ensured by a strict control of the whole plant process:
contractual partnerships with local subcontractors, expertise in
vegetable lipid chemistry allowing an exact deﬁnition of the plant
species extracted and the soils together with the application of
GMP rules for the whole process from the plant starting material
up to the pharmaceutical active ingredient.
Attracted by the scientiﬁc renown and success of pharmaceutical
ASU, nutraceutical companies have attempted to develop imita-
tions by suggesting more or less clearly a relation between the
composition and even the activity of the original pharmaceutical.
Methods: An analytical study of 7 nutraceutical products (for
human and veterinary uses) claiming the name ASU has been
performed by gas chromatography methodology.
Results: The analytical study of the nutraceutical products ver-
sus the original and authentic ASU showed:
– The complete absence of speciﬁc molecules which are
patented (obtained by transformation of avocado precursors)
evaluated by GC assay of silylderivatives on a 5%-phenyl-
methylpolysiloxane capillary column equipped with a cold on-
column injector and a FID detector;
– A content of unsaponiﬁables of less than 25% measured by a
method of the American Oil Chemistry Society N° Ca 6a-40;
– A lower sterol and tocopherol content of less than 15% and 5%
